Oncotarget

Reviews:

Expression profile and functional role of S100A14 in human cancer

Suyog Basnet, Sunita Sharma, Daniela Elena Costea and Dipak Sapkota _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:2996-3012. https://doi.org/10.18632/oncotarget.26861

Metrics: PDF 335 views  |   HTML 1148 views  |   ?  


Abstract

Suyog Basnet1, Sunita Sharma2, Daniela Elena Costea3,4,5 and Dipak Sapkota6

1Department of BioSciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

2Department of Clinical Dentistry, Centre for Clinical Dental Research, University of Bergen, Bergen, Norway

3Gade Laboratory for Pathology, Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway

4Centre for Cancer Biomarkers (CCBIO), Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway

5Department of Pathology, Haukeland University Hospital, Bergen, Norway

6Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway

Correspondence to:

Dipak Sapkota, email: Dipak.sapkota@odont.uio.no

Keywords: S100 proteins; cancer; differentiation; expression; prognosis

Received: October 08, 2018    Accepted: March 23, 2019    Published: April 26, 2019

ABSTRACT

S100A14 is one of the new members of the multi-functional S100 protein family. Expression of S100A14 is highly heterogeneous among normal human tissues, suggesting that the regulation of S100A14 expression and its function may be tissue- and context-specific. Compared to the normal counterparts, S100A14 mRNA and protein levels have been found to be deregulated in several cancer types, indicating a functional link between S100A14 and malignancies. Accordingly, S100A14 is functionally linked with a number of key signaling molecules such as p53, p21, MMP1, MMP9, MMP13, RAGE, NF-kB, JunB, actin and HER2. Of interest, S100A14 seems to have seemingly opposite functions in malignancies arising from the gastrointestional tract (tissues rich in epithelial components) compared to cancers in the other parts of the body (tissues rich in mesenchymal components). The underlying mechanism for these observations are currently unclear and may be related to the relative abundance and differences in the type of interaction partners (effector protein) in different cancer types and tissues. In addition, several studies indicate that the expression pattern of S100A14 has a potential to be clinically useful as prognostic biomarker in several cancer types. This review attempts to provide a comprehensive summary on the expression pattern and functional roles/related molecular pathways in different cancer types. Additionally, the prognostic potential of S100A14 in the management of human malignancies will be discussed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26861